Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company presented “impressive” data from ATTR patients treated with nex-z in Phase I, demonstrating durable effects on clinical metrics and biomarkers beyond TTR reduction in both patient subsets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer
- Intellia Therapeutics price target lowered to $55 from $76 at Barclays
- Intellia Therapeutics Reports Q3 2024 Financial Progress
- Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch
- Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39)